Fortrea (FTRE)

Nasdaq Health Care Biotechnology S&P SmallCap 600
$21.96
+1.50 (+7.33%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Trailing 12-month EPS
$-0.66
Diluted, last four reported quarters

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Oct 29, 2026Sep/2026$0.24$0.28+16.7%

Our record of FTRE's reports since we began tracking; it grows each quarter.

Latest results, in brief

All FTRE 8-K briefs →
Oct 29, 6:38 AM ET

Fortrea Q3 revenue falls to $691.5 million; full-year guidance midpoints raised

Mixed earnings 2.02

Fortrea reported third-quarter 2026 revenue of $691.5 million, down from $701.3 million a year earlier, while adjusted diluted EPS rose to $0.28 from $0.12 and GAAP net income was $0.6 million, compared with a $15.9 million loss. The company raised the midpoints of its 2026 revenue and adjusted EBITDA guidance and narrowed the ranges. It also reduced backlog by $558 million after a contract review, which it said does not affect historical results or 2026 guidance.

  • Q3 revenue was $691.5 million, compared with $701.3 million in Q3 2025
  • Adjusted diluted EPS was $0.28 vs. $0.12; adjusted EBITDA was $58.0 million vs. $50.7 million
  • 2026 guidance: revenue of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million, with midpoints raised
  • Backlog was reduced by $558 million to $7,316 million; book-to-bill ratio was 1.12x
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$691.50M-1.4% $0.01— $600.00K0.1%
Jun 2026$678.20M-4.5% $-0.14— -$13.20M-1.9%
Mar 2026$636.50M-2.3% $-0.25— -$23.60M-3.7%
Dec 2025$660.50M-5.2% $-0.28— -$32.50M-4.9%
Sep 2025$701.30M+3.9% $-0.17— -$15.90M-2.3%
Jun 2025$710.30M+7.2% $-4.14— -$374.90M-52.8%
Mar 2025$651.30M-1.6% $-6.25— -$562.90M-86.4%
Dec 2024$697.00M-1.8% $-0.68— -$61.20M-8.8%

From Fortrea's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$2.72B+1.0% $-10.81—-36.2%
FY2024$2.70B-5.1% $-3.67—-12.2%
FY2023$2.84B+0.2% $-0.29-113.9%-0.9%
FY2022$2.84B-7.2% $2.09+90.0%6.6%
FY2021$3.06B— $1.10—3.2%

Frequently asked questions

When is Fortrea's next earnings date?

Fortrea has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Fortrea earn last quarter?

For the quarter ended Sep 2026, Fortrea reported diluted EPS of $0.01 on revenue of $691.50M (-1.4%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.